SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
PRINCETON, N.J., Dec. 22, 2016 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al Altomari will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017 at 11:30 AM Pacific Time. The conference will be held at the Westin St. Francis in San Francisco, CA.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile
Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com.
Contact: Mary Coleman 609-683-1880
